局部晚期胰腺癌患者姑息治疗和支持治疗使用不足:国家癌症数据统计数据库(NCDB☆)回顾

C.G. Cann , C. Shen , M. LaPelusa , D. Cardin , J. Berlin , R. Agarwal , C. Eng
{"title":"局部晚期胰腺癌患者姑息治疗和支持治疗使用不足:国家癌症数据统计数据库(NCDB☆)回顾","authors":"C.G. Cann ,&nbsp;C. Shen ,&nbsp;M. LaPelusa ,&nbsp;D. Cardin ,&nbsp;J. Berlin ,&nbsp;R. Agarwal ,&nbsp;C. Eng","doi":"10.1016/j.esmogo.2024.100049","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Nearly one-third of patients with newly diagnosed pancreatic cancer present with locally advanced disease (LAPC), with 25% eligible for surgical resection, lending to a poor 5-year overall survival of 16.2%. Given the significant morbidity and mortality associated with LAPC, timely integration of palliative and supportive care (SC) into the treatment care plan is vital. The purpose of this study was to investigate the utilization of SC in patients with LAPC and identify the demographic and socioeconomic factors that influence its application.</p></div><div><h3>Patients and methods</h3><p>A retrospective database analysis of the National Cancer Database (NCDB) was carried out. Data regarding patients diagnosed with stage II-III LAPC between 2004 and 2018 were used. Analyses included tumor characteristics, demographics, socioeconomic parameters, and trends in utilization of SC.</p></div><div><h3>Results</h3><p>A total of 111 964 patients were included [stage II (72.3%); stage III (27.6%)]. Only 7.72% received SC despite 67% of patients receiving cancer-directed treatment at an academic or integrated network cancer program, 84% living in or near a metro area, and 60% living ≤20 miles of their primary treatment center. Rates of SC utilization remained &lt;8% and &lt;12% in stage II and III disease, respectively, throughout the two decades.</p></div><div><h3>Conclusions</h3><p>SC has been underutilized in the LAPC population over the past two decades, despite the increase in data supporting early integration of palliative care and the potential sociodemographic areas of unmet need. Future work should focus on evaluating practice patterns across cancer centers and the potential positive impact of early SC integration on both survival and quality-of-life outcomes for patients with LAPC.</p></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"4 ","pages":"Article 100049"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949819824000104/pdfft?md5=a14f6ed69e3577001eafae6699246017&pid=1-s2.0-S2949819824000104-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB☆\",\"authors\":\"C.G. Cann ,&nbsp;C. Shen ,&nbsp;M. LaPelusa ,&nbsp;D. Cardin ,&nbsp;J. Berlin ,&nbsp;R. Agarwal ,&nbsp;C. Eng\",\"doi\":\"10.1016/j.esmogo.2024.100049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Nearly one-third of patients with newly diagnosed pancreatic cancer present with locally advanced disease (LAPC), with 25% eligible for surgical resection, lending to a poor 5-year overall survival of 16.2%. Given the significant morbidity and mortality associated with LAPC, timely integration of palliative and supportive care (SC) into the treatment care plan is vital. The purpose of this study was to investigate the utilization of SC in patients with LAPC and identify the demographic and socioeconomic factors that influence its application.</p></div><div><h3>Patients and methods</h3><p>A retrospective database analysis of the National Cancer Database (NCDB) was carried out. Data regarding patients diagnosed with stage II-III LAPC between 2004 and 2018 were used. Analyses included tumor characteristics, demographics, socioeconomic parameters, and trends in utilization of SC.</p></div><div><h3>Results</h3><p>A total of 111 964 patients were included [stage II (72.3%); stage III (27.6%)]. Only 7.72% received SC despite 67% of patients receiving cancer-directed treatment at an academic or integrated network cancer program, 84% living in or near a metro area, and 60% living ≤20 miles of their primary treatment center. Rates of SC utilization remained &lt;8% and &lt;12% in stage II and III disease, respectively, throughout the two decades.</p></div><div><h3>Conclusions</h3><p>SC has been underutilized in the LAPC population over the past two decades, despite the increase in data supporting early integration of palliative care and the potential sociodemographic areas of unmet need. Future work should focus on evaluating practice patterns across cancer centers and the potential positive impact of early SC integration on both survival and quality-of-life outcomes for patients with LAPC.</p></div>\",\"PeriodicalId\":100490,\"journal\":{\"name\":\"ESMO Gastrointestinal Oncology\",\"volume\":\"4 \",\"pages\":\"Article 100049\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949819824000104/pdfft?md5=a14f6ed69e3577001eafae6699246017&pid=1-s2.0-S2949819824000104-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Gastrointestinal Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949819824000104\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819824000104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景近三分之一的新诊断胰腺癌患者为局部晚期疾病(LAPC),其中 25% 的患者符合手术切除条件,5 年总生存率仅为 16.2%。鉴于局部晚期胰腺癌的发病率和死亡率都很高,及时将姑息治疗和支持治疗(SC)纳入治疗计划至关重要。本研究旨在调查姑息和支持性治疗在 LAPC 患者中的应用情况,并确定影响其应用的人口和社会经济因素。使用了2004年至2018年期间诊断为II-III期LAPC患者的数据。分析内容包括肿瘤特征、人口统计学、社会经济参数以及使用 SC 的趋势。结果共纳入 111 964 例患者[II 期(72.3%);III 期(27.6%)]。尽管67%的患者在学术或综合网络癌症项目中接受癌症定向治疗,84%的患者居住在大都市或附近地区,60%的患者居住地距离主要治疗中心不足20英里,但只有7.72%的患者接受了SC治疗。在过去二十年中,尽管支持早期整合姑息治疗的数据不断增加,而且潜在的社会人口学领域存在未满足的需求,但II期和III期患者的SC使用率仍分别为8%和12%。未来的工作应侧重于评估各癌症中心的实践模式,以及早期整合姑息治疗对 LAPC 患者生存和生活质量的潜在积极影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB☆

Background

Nearly one-third of patients with newly diagnosed pancreatic cancer present with locally advanced disease (LAPC), with 25% eligible for surgical resection, lending to a poor 5-year overall survival of 16.2%. Given the significant morbidity and mortality associated with LAPC, timely integration of palliative and supportive care (SC) into the treatment care plan is vital. The purpose of this study was to investigate the utilization of SC in patients with LAPC and identify the demographic and socioeconomic factors that influence its application.

Patients and methods

A retrospective database analysis of the National Cancer Database (NCDB) was carried out. Data regarding patients diagnosed with stage II-III LAPC between 2004 and 2018 were used. Analyses included tumor characteristics, demographics, socioeconomic parameters, and trends in utilization of SC.

Results

A total of 111 964 patients were included [stage II (72.3%); stage III (27.6%)]. Only 7.72% received SC despite 67% of patients receiving cancer-directed treatment at an academic or integrated network cancer program, 84% living in or near a metro area, and 60% living ≤20 miles of their primary treatment center. Rates of SC utilization remained <8% and <12% in stage II and III disease, respectively, throughout the two decades.

Conclusions

SC has been underutilized in the LAPC population over the past two decades, despite the increase in data supporting early integration of palliative care and the potential sociodemographic areas of unmet need. Future work should focus on evaluating practice patterns across cancer centers and the potential positive impact of early SC integration on both survival and quality-of-life outcomes for patients with LAPC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials Practical management of oligometastatic gastric cancer Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study Gastrin-releasing peptide receptor expression in gastrointestinal stromal tumours
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1